Skip to content
Subscriber Only
Max Nisen

Eli Lilly's Blockbuster Resurrection Story Has Holes

Its arthritis drug's new lease on FDA life apparently comes with conditions.
Photographer: Michael Nagle

Eli Lilly & Co.'s arthritis drug Olumiant -- a would-be blockbuster developed with Incyte Corp. -- miraculously emerged from the graveyard in August after the FDA un-rejected the medicine and agreed to consider it for approval. 

But rising from the dead is not so simple.